英夫利西单抗治疗克罗恩病的临床评价

Clinical evaluation of infliximab in treatment of Crohn’s disease

目的评价英夫利西单抗治疗克罗恩病(CD)的疗效及安全性。方法回顾性分析完成6次英夫利西单抗(IFX)治疗的50例CD患者资料。所有患者均给予IFX 5 mg·kg-1静脉滴注,第0、2、6周(即前3次治疗)诱导缓解,随后每隔8周给予相同剂量维持治疗,连续3次。比较患者治疗前及IFX治疗3次和6次后的体重、实验室指标、CD活动指数(CDAI)和临床缓解率。收集IFX使用期间发生的所有不良反应。结果与治疗前相比,IFX治疗3次及6次后的体重、血红蛋白(HGB)、血细胞比容(HCT)、白蛋白(ALB)、C反应蛋白(CRP)、CDAI和临床缓解率皆显著改善(P<0.05)。IFX治疗6次与3次后相比,CDAI显著改善(P<0.05)。共有9例(18%)患者出现不良反应,给予对症处理后皆恢复正常。结论 IFX治疗CD可取得较好的临床疗效,且安全性较好。

AIM To evaluate the efficacy and safety of infliximab in the treatment of Crohn’s disease.METHODS Fifty patients with Crohn’s disease in a hospital who had completed 6 sessions of infliximab treatment were selected.All patients were given infliximab 5 mg·kg-1 intravenously,which induced induction therapy at 0,2,and 6 weeks(the first 3 treatments),followed by maintenance therapy at an 8 weeks interval for 3 consecutive times.Weight,laboratory indicators,Crohn’s disease activity index(CDAI) and clinical remission rate of patients treated with the third and sixth sessions of infliximab were compared before treatment,and the efficacy was evaluated.All adverse reactions occurred during the process of infliximab use were collected and the safety was evaluated.RESULTS A total of 50 patients were included.After the third and sixth infliximab treatment,all curative effect indicators such as body weight,hemoglobin(HGB),hematocrit(HCT),albumin(ALB),C-reactive protein(CRP),CDAI and clinical remission rate were significantly improved than before treatment(P < 0.05).Compared to after the third treatment,CDAI of after the sixth infliximab treatment was significantly improved(P < 0.05).A total of 9 patients had adverse reactions,with an incidence of 18%,and all of them returned to normal after symptomatic treatment.CONCLUSION Infliximab is effective in the treatment of Crohn’s disease,and the safety is better.